Leishmaniases are a clinically heterogeneous group of diseases caused by protozoa of the genus Leishmania. There is growing evidence that the true incidence of the disease is underestimated, especially in hyperendemic regions. Moreover, climate changes together with the increasing movement of humans and animals raise concerns about the possible introduction of Leishmania infection in previously spared areas. The disease is emerging in immunocompromised patients undergoing bone marrow or solid organ transplantation or treatment with biologic drugs. Furthermore, the deployment of military troops and travel to endemic areas are associated with the observation of a growing number of patients with cutaneous disease. Improvement in diagnostic methods, both in the field and in specialized laboratories, has been obtained through the implementation of molecular amplification methods and using the rK39 antigen as the substrate. Finally, new therapeutic approaches are gaining attention, such as the use of miltefosine for cutaneous leishmaniasis and paromomycin for visceral leishmaniasis, as well as the use of various antileishmanial drugs in combination

Leishmaniasis : new insights from an old and neglected disease / S. Antinori, L. Schifanella, M. Corbellino. - In: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. - ISSN 0934-9723. - 31:2(2012 Feb), pp. 109-118. [10.1007/s10096-011-1276-0]

Leishmaniasis : new insights from an old and neglected disease

S. Antinori
Primo
;
L. Schifanella;
2012

Abstract

Leishmaniases are a clinically heterogeneous group of diseases caused by protozoa of the genus Leishmania. There is growing evidence that the true incidence of the disease is underestimated, especially in hyperendemic regions. Moreover, climate changes together with the increasing movement of humans and animals raise concerns about the possible introduction of Leishmania infection in previously spared areas. The disease is emerging in immunocompromised patients undergoing bone marrow or solid organ transplantation or treatment with biologic drugs. Furthermore, the deployment of military troops and travel to endemic areas are associated with the observation of a growing number of patients with cutaneous disease. Improvement in diagnostic methods, both in the field and in specialized laboratories, has been obtained through the implementation of molecular amplification methods and using the rK39 antigen as the substrate. Finally, new therapeutic approaches are gaining attention, such as the use of miltefosine for cutaneous leishmaniasis and paromomycin for visceral leishmaniasis, as well as the use of various antileishmanial drugs in combination
WORLD CUTANEOUS LEISHMANIASIS; LIPOSOMAL AMPHOTERICIN-B; RECONSTITUTION INFLAMMATORY SYNDROME; INDIAN VISCERAL LEISHMANIASIS; ACTIVE ANTIRETROVIRAL THERAPY; OF-THE-LITERATURE; HIV-INFECTION ; IMMUNOCOMPROMISED PATIENTS; DERMAL LEISHMANIASIS; EMERGING INFECTION
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
leihmaniasis 2.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 266.87 kB
Formato Adobe PDF
266.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/160521
Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 87
social impact